In a study of the Pfizer and AstraZeneca vaccines, 96.42 percent of people who received either vaccine developed antibodies. Indeed, the antibodies were produced between 28 and 34 days from the first dose, which was praised by academics involved in the study. Dr Maddie Shrotri said: “This is one of the first real world vaccine studies in the UK and this is great news. ”
With the UK vaccination rate soaring, antibody production is seen as a longer term mark of future immunity to the virus.
Data from the University College London (UCL) study also support the theory that both vaccines are highly effective against the virus, despite some skepticism about the drug AstraZeneca in Europe.
Dr Shrotri said: ‘More than nine in 10 adults in the UK who had received the Pfizer or AstraZeneca vaccine produced antibodies to the virus within one month of their first injection.
“It is a real feat of science in the face of the most devastating pandemic in a century. “
In another boost, the average age of the study was 65, meaning those most at risk who received their vaccine may now have antibodies.
The academics also reiterated the importance of receiving the second dose of the vaccine on time due to the increased production of antibodies.
JUST IN: Brexit LIVE: Macron threatens to sink funding deal with UK
However, the government is still unsure of the effectiveness of the vaccines against the Indian variant.
Studies are ongoing as surge vaccinations have been sent to areas such as Bolton to combat the increase in cases.
There are also concerns about the lack of vaccination in areas where the Indian variant has been discovered.
They told Politico that the number of requests had increased dramatically in Bolton over the past three days.